On April 1, 2024, the Board (excluding our Chief Executive Officer and Chairman of the Board Monty J. Bennett, who recused himself from the Board vote), upon the recommendation of a Special Committee of the Board consisting entirely of independent and disinterested directors, approved a transaction whereby the Company would effect a 1-for-10,000 reverse stock split of the Company's outstanding $0.001 par value common stock (the "Reverse Stock Split"), subject to obtaining the requisite approval of the Company's stockholders at a Special Meeting of Stockholders to be held for that purpose, which is currently expected to occur in the summer of 2024. If the Reverse Stock Split is approved at the Special Meeting and effectuated, the Board has approved a 10,000-for-1 forward stock split of our common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Transaction") to occur immediately after the Reverse Stock Split. The Forward Stock Split will reconvert whole shares and fractional share interests held by Stockholders owning in any one account 10,000 or more shares immediately prior to the effective time of the Reverse Stock Split ("Continuing Stockholders") back into the same number of shares of the Company's common stock held by such Continuing Stockholders immediately prior to the Reverse Stock Split. As a result of the Forward Stock Split, the total number of shares of the Company's common stock held by a Continuing Stockholder prior to the Reverse Stock Split will not change following the completion of the Transaction.
Although the Transaction cannot occur without the requisite approval of the Reverse Stock Split by stockholders at the Special Meeting, even if such approval is obtained, the Board has reserved the right not to proceed with the Transaction if it believes it is no longer in the best interests of the Company.
The intended effect of the Transaction is to reduce the number of record holders of the Company's common stock (509 as of April 5, 2024) to fewer than 300 so that the Company would be eligible to terminate the public registration of the Company's common stock under Section 12(g) of the Exchange Act, suspend the Company's duty to file periodic reports and other information with the SEC under Section 13(a) of the Exchange Act, and delist the Company's common stock from the NYSE American. Following the Transaction, we currently intend to continue to have our financial statements audited by a public accounting firm, but we do not intend to make such financial statements available to our stockholders, unless required by law or otherwise agreed to by the Company. The Company expects that the deregistration of its common stock under the Exchange Act would eliminate the significant expense required to comply with its Exchange Act reporting obligations and the SEC's proxy rules. The Company estimates the annual savings would be approximately $2.5 million per year, including ongoing expenses for compliance with the Sarbanes-Oxley Act, and other accounting, legal, printing and other miscellaneous costs associated with being a publicly traded company.
Stockholders owning fewer than 10,000 shares of the Company's common stock in any one account immediately prior to the effective time of the Reverse Stock Split will receive $5.00 in cash, without interest, for each share held at the effective time of the Reverse Stock Split, and they will no longer be stockholders of the Company. Continuing Stockholders will not receive any payment for their shares and, immediately following the Transaction, will continue to hold the same number of shares as before the Transaction. Stockholders who want to be Continuing Stockholders can attempt to purchase additional shares in order to have at least 10,000 shares at the effective time of the Reverse Stock Split; however, given the historically limited liquidity in our stock, we cannot assure stockholders that any shares will be available for purchase and thus there is a risk that stockholders may not be able to purchase sufficient shares to achieve or exceed the required 10,000 shares. Any trading in our common stock after the Transaction and deregistration under the Exchange Act will only occur in privately negotiated sales and potentially on the OTC Pink Market, if one or more brokers chooses to make a market for our common stock there and complies with applicable regulatory requirements; however, there can be no assurances regarding any such trading.
Stockholders holding the Company's common stock following the Transaction and subsequent filing to become a non-reporting entity may no longer have the information that is currently provided in the Company's filings with the SEC pursuant to the Exchange Act regarding such matters as the Company's business operations and developments, legal proceedings involving the Company, the Company's financial results, the compensation of the Company's directors and named executive officers, and Company securities held by the Company's directors, officers and major stockholders. In addition, it is likely that there will be limited liquidity for the Company's common stock and that trading of shares may only continue in privately negotiated sales. As a result, stockholders may not be able to purchase or sell the common stock at all or at prices they desire.
Further, the Company's stockholders will no longer have the protections provided by the liability provisions of the Exchange Act and the Sarbanes-Oxley Act applicable to the Company and the Company's directors, officers and major stockholders, including the short-swing profit provisions of Section 16, the proxy solicitation rules under Section 14, the stock ownership reporting rules under Section 13, provisions relating to personal attestation by officers about accounting controls and procedures potential criminal liability regarding the disclosure by the Company.